11/19/2009
wendella a. says:
Paul - Genentech are evil bastards? Hardly. Some facts about Genentech:
* 1982 - Synthetic "human" insulin approved by the U.S. Food and Drug Administration (FDA), thanks largely to its partnership with insulin manufacturer Eli Lilly and Company, who shepherded the product through the FDA approval process. The product (Humulin) was licensed to and manufactured by Lilly, and was the first-ever approved genetically engineered human therapeutic.
* 1985 - Protropin (somatrem) - Supplementary growth hormone for children with growth hormone deficiency (ceased manufacturing 2004).
* 1987 - Activase (alteplase) - A recombinant tissue plasminogen activator (tPa) used to dissolve blood clots in patients with acute myocardial infarction. Also used to treat non-hemorrhagic stroke.
* 1990 - Actimmune (interferon gamma 1b) - Treatment of chronic granulomatous disease (licensed to Intermune).
* 1993 - Nutropin (recombinant somatropin) - Growth hormone for children and adults for treatment before kidney transplant due to chronic renal insufficiency.
* 1993 - Pulmozyme (dornase alfa) - Inhalation treatment for children and young adults with cystic fibrosis - recombinant DNAse.
* 1997 - Rituxan (rituximab)- Treatment for specific kinds of non-Hodgkins lymphomas. In 2006, also approved for rheumatoid arthritis.
* 1998 - Herceptin (trastuzumab) - Treatment for metastatic breast cancer patients with tumors that overexpress the HER2 gene. Recently approved for adjuvant therapy for breast cancer.
* 2000 - TNKase (tenecteplase) - "Clot-busting" drug to treat acute myocardial infarction.
* 2003 - Xolair (omalizumab) - Subcutaneous injection for moderate to severe persistent asthma.
* 2003 - Raptiva (efalizumab) - Antibody designed to block the activation and reactivation of T cells that lead to the development of psoriasis. Developed in partnership with XOMA. In 2009, voluntary U.S. market withdrawal after reports of progressive multifocal leukoencephalopathy.
* 2004 - Avastin (bevacizumab) - Anti-VEGF monoclonal antibody for the treatment of metastatic cancer of the colon or rectum. In 2006, also approved for locally advanced, recurrent or metastatic non-small cell lung cancer. In 2008, accelerated approval was granted for Avastin in combination with chemotherapy for previously untreated advanced HER2-negative breast cancer. In 2009, Avastin gained its fifth approval for treatment of glioblastoma multiforme, and sixth approval for the treatment of metastatic renal cell carcinoma.
* 2004 - Tarceva (erlotinib) - Treatment for patients with locally advanced or metastatic non-small cell lung cancer, and pancreatic cancer.
* 2006 - Lucentis (ranibizumab injection) - The U.S. Food and Drug Administration (FDA) has approved LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA approved LUCENTIS after a Priority Review (six-month).